Eledon Pharmaceuticals Inc. (ELDN) Financial Statements (2024 and earlier)

Company Profile

Business Address 19800 MACARTHUR BLVD.
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:51,100,00056,409,00084,833,000114,195,0008,791,00012,972,000
Cash and cash equivalents4,612,00056,409,00084,833,000114,195,0008,791,00012,972,000
Short-term investments46,490,000     
Other undisclosed cash, cash equivalents, and short-term investments(2,000)     
Receivables    110,000245,000 
Prepaid expense809,000966,0001,440,0001,198,000779,000674,000
Other current assets90,00028,00034,00038,00054,000630,000
Other undisclosed current assets4,130,0002,115,0002,039,00089,000102,000 
Total current assets:56,129,00059,518,00088,346,000115,630,0009,971,00014,276,000
Noncurrent Assets
Operating lease, right-of-use asset365,000739,000768,000138,000316,000
Property, plant and equipment     5,00014,000
Intangible assets, net (including goodwill)   48,648,00048,648,000 1,867,000
Goodwill   48,648,00048,648,000 1,867,000
Other noncurrent assets186,000150,000400,000383,000639,000869,000
Other undisclosed noncurrent assets32,386,00032,386,00032,386,00032,386,000  
Total noncurrent assets:32,937,00033,275,00082,202,00081,555,000960,0002,750,000
TOTAL ASSETS:89,066,00092,793,000170,548,000197,185,00010,931,00017,026,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,061,0004,286,0003,474,0001,619,000705,0001,799,000
Employee-related liabilities1,411,00098,000239,000902,000
Accounts payable967,0002,200,0001,813,0001,366,000329,000689,000
Accrued liabilities2,094,0002,086,000250,000155,000137,000208,000
Debt     180,000 
Other undisclosed current liabilities834,0002,189,000927,000864,000437,000 
Total current liabilities:3,895,0006,475,0004,401,0002,483,0001,322,0001,799,000
Noncurrent Liabilities
Long-term debt and lease obligation:   400,000 144,000 
Liabilities, other than long-term debt1,752,0002,135,0001,752,0004,106,000  
Deferred income tax liabilities1,752,0001,752,0001,752,0004,106,000 
Operating lease, liability 383,000400,000 144,000
Other undisclosed noncurrent liabilities76,211,000     
Total noncurrent liabilities:77,963,0002,135,0002,152,0004,106,000144,000 
Other undisclosed liabilities      735,000
Total liabilities:81,858,0008,610,0006,553,0006,589,0001,466,0002,534,000
Equity
Equity, attributable to parent, including:7,208,00084,183,000163,995,000190,596,0009,465,00014,492,000
Common stock24,00014,00014,00015,00013,0009,000
Additional paid in capital326,586,000287,034,000278,880,000270,974,00067,034,00056,054,000
Accumulated deficit(319,402,000)(202,865,000)(114,899,000)(80,393,000)(57,582,000)(41,571,000)
Warrants and rights outstanding76,211,000     
Other undisclosed equity, attributable to parent(76,211,000)     
Total equity:7,208,00084,183,000163,995,000190,596,0009,465,00014,492,000
TOTAL LIABILITIES AND EQUITY:89,066,00092,793,000170,548,000197,185,00010,931,00017,026,000

Income Statement (P&L) (USD)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(43,000,000)(88,428,000)(36,867,000)(18,465,000)(16,051,000)(14,060,000)
Operating loss:(43,000,000)(88,428,000)(36,867,000)(18,465,000)(16,051,000)(14,060,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
2,674,000462,0007,00079,00040,000(5,000)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (4,829,000)  
Loss from continuing operations before equity method investments, income taxes:(40,326,000)(87,966,000)(36,860,000)(23,215,000)(16,011,000)(14,065,000)
Other undisclosed loss from continuing operations before income taxes(76,211,000)     
Loss from continuing operations before income taxes:(116,537,000)(87,966,000)(36,860,000)(23,215,000)(16,011,000)(14,065,000)
Income tax benefit   2,354,000404,000  
Loss from continuing operations:(116,537,000)(87,966,000)(34,506,000)(22,811,000)(16,011,000)(14,065,000)
Loss before gain (loss) on sale of properties:(34,506,000)(22,811,000)(16,011,000)(14,065,000)
Net loss:(116,537,000)(87,966,000)(34,506,000)(22,811,000)(16,011,000)(14,065,000)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, diluted:(116,537,000)(87,966,000)(34,506,000)(22,811,000)(16,011,000)(14,065,000)

Comprehensive Income (USD)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(116,537,000)(87,966,000)(34,506,000)(22,811,000)(16,011,000)(14,065,000)
Comprehensive loss, net of tax, attributable to parent:(116,537,000)(87,966,000)(34,506,000)(22,811,000)(16,011,000)(14,065,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: